Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Enterprise Value: 2009-2025

Historic Enterprise Value for Aytu Biopharma (AYTU) over the last 16 years, with Sep 2025 value amounting to -$14.0 million.

  • Aytu Biopharma's Enterprise Value fell 147.37% to -$14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.5 million, marking a year-over-year decrease of 28.58%. This contributed to the annual value of -$17.5 million for FY2025, which is 367.07% down from last year.
  • Per Aytu Biopharma's latest filing, its Enterprise Value stood at -$14.0 million for Q3 2025, which was up 20.03% from -$17.5 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Enterprise Value peaked at $89.1 million during Q1 2021, and registered a low of -$17.5 million during Q2 2025.
  • For the 3-year period, Aytu Biopharma's Enterprise Value averaged around -$9.6 million, with its median value being -$9.9 million (2024).
  • As far as peak fluctuations go, Aytu Biopharma's Enterprise Value soared by 158.12% in 2021, and later crashed by 382.90% in 2022.
  • Over the past 5 years, Aytu Biopharma's Enterprise Value (Quarterly) stood at $2.7 million in 2021, then crashed by 382.90% to -$7.7 million in 2022, then spiked by 51.73% to -$3.7 million in 2023, then slumped by 167.51% to -$9.9 million in 2024, then slumped by 147.37% to -$14.0 million in 2025.
  • Its Enterprise Value stands at -$14.0 million for Q3 2025, versus -$17.5 million for Q2 2025 and -$10.8 million for Q1 2025.